A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors

Trial Profile

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Aug 2017

At a glance

  • Drugs Andecaliximab (Primary) ; Bevacizumab; Carboplatin; Fluorouracil; Folinic acid; Gemcitabine; Irinotecan; Oxaliplatin; Paclitaxel; Pemetrexed
  • Indications Adenocarcinoma; Breast cancer; Colorectal cancer; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 13 Apr 2017 Planned number of patients changed from 250 to 261.
    • 05 Apr 2017 Results of exploratory serum biomarker analysis in gastric cancer patients treated with GS-5745 (n=40), presented at the 108th Annual Meeting of the American Association for Cancer Research.
    • 21 Jan 2017 Results of a cohort of patients with pancreatic cancer (n=36) presented at the 2017 Gastrointestinal Cancers Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top